FDAsafety guidance66% confidence
FDA TA — CARBIDOPA; LEODOPA (ORIG)
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Zydus Pharmaceuticals; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Application ANDA210911. Sponsor: ZYDUS PHARMS USA INC. Submission status: TA. Submission type: ORIG. Review priority: STANDARD. Active ingredients: CARBIDOPA, LEODOPA.
Supporting Context
- Therapeutic area
- Immunology · Corticosteroid
- Sub-indication
- General
Related signal: FDA Grants AP Status for Zydus' Methylprednisolone ANDA206751